Botulinum Toxin Therapy in Hidradenitis Suppurativa
Targeting Nociceptors in Hidradenitis Suppurativa
University of Massachusetts, Worcester
20 participants
Jun 7, 2022
OBSERVATIONAL
Conditions
Summary
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Eligibility
Inclusion Criteria2
- Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS)
- HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas
Exclusion Criteria8
- Age \< 18 years or \> 75 years
- pregnant or breastfeeding
- neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome, myopathy)
- medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy)
- active bacterial, fungal, or viral infection in the treatment area
- known hypersensitivity to botulinum toxin A preparations or any of their components (human albumin, saline, lactose, sodium succinate)
- prisoners
- adults unable to consent for themselves.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05403710